research use only
Cat.No.S4004
| Related Targets | Integrase Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease |
|---|---|
| Other Bacterial Inhibitors | Berberine BTZ043 Racemate Teicoplanin Pefloxacin Mesylate Furagin Ornidazole Proanthocyanidins Solithromycin Skatole Berberine Sulfate |
|
In vitro |
DMSO
: 56 mg/mL
(201.99 mM)
Water : 56 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 277.23 | Formula | C10H24N2O2.2HCl |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1070-11-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | CL40881 | Smiles | CCC(CO)NCCNC(CC)CO.Cl.Cl | ||
| In vitro |
Ethambutol directly affects two polymers, arabinogalactan (AG) and lipoarabinomannan (LAM) in Mycobacterium smegmatis. In M. smegmatis, Ethambutol inhibits synthesis of arabinan completely and inhibits AG synthesis most likely as a consequence of this; more than 50% of the cell arabinan is released from the bacteria following Ethambutol treatment, whereas no galactan is released. Ethambutol main targets against embB gene product in M. avium. Ethambutol induces 60% changes in the embB gene in M. tuberculosis resistant mutants.
Ethambutol is effective against actively growing microorganisms of the genus Mycobacterium, including M. tuberculosis. Nearly all strains of M. tuberculosis and M. kansasii as well as a number of strains of the M. aviumcomplex (MAC) are sensitive to Ethambutol. Ethambutol is potency against M. tuberculosis (H37Rv) with MIC of 0.5 μg/mL in vitro.
Ethambutol is efficient on treatment of mycobacterial-infected macrophages. When M. tuberculosis infected macrophages are treated with 6 μg/mL Ethambutol, the log CFUs following treatment for 3 days is 4.17, while value in control group is 4.8. The MICs for M. avium (MTCC 1723) and M. smegmatis (MTCC 6) are 15 μg/mL and 0.18 μg/mL, respectively.
|
|---|---|
| In vivo |
Ethambutol is efficient in animal model. 100 mg/kg Ethambutol given orally 15 days post i.v. infection 1 ×/week for 5 weeks, induces a lower log CFU compared with untreatment (4.59 vs 5.07).
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05840809 | Recruiting | Tuberculosis Active|Breastfeeding|Tuberculosis |
University of Liverpool|Infectious Diseases Institute Makerere University College of Health Sciences |
January 20 2022 | -- |
| NCT04972903 | Unknown status | Tuberculosis|Pulmonary |
Institut National de la Santé Et de la Recherche Médicale France|National Agency for Research on AIDS and Viral Hepatitis (ANRS) |
August 2021 | -- |
| NCT02114684 | Completed | Recurrent Tuberculosis |
Centre for the AIDS Programme of Research in South Africa |
November 2013 | Phase 1|Phase 2 |
| NCT02496572 | Unknown status | Multidrug Resistant Tuberculosis |
Medecins Sans Frontieres Netherlands|Ministry of Health Republic of Uzbekistan|Imperial College London |
September 2013 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.